Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THX-110 (Dronabinol + PEA) in Tourette Syndrome
NCT03066193Phase 2Completed
- Sponsor
- Yale University
- Start
- Feb 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dronabinol and palmitoylethanolamide in Tourette syndrome (TS), sponsored by Yale University. Primary endpoint: Yale Global Tic Severity Scale Total Tic Score at 12 weeks. Started Feb 2017; status: completed.
02
Drugs
dronabinolpalmitoylethanolamide
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT03066193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03066193.